Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O60243: Variant p.Arg306Trp

Heparan-sulfate 6-O-sulfotransferase 1
Gene: HS6ST1
Feedback?
Variant information Variant position: help 306 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Tryptophan (W) at position 306 (R306W, p.Arg306Trp). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to large size and aromatic (W) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In HH15; with anosmia; results in Kallmann syndrome in the presence of FGFR1 mutation Gln-250; approximately 50% reduction in enzymatic activity compared to wild-type. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 306 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 411 The length of the canonical sequence.
Location on the sequence: help RGMAFFGLTEFQRKTQYLFE R TFNLKFIRPFMQYNSTRAGG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         RGMAFFGLTEFQRKTQYLFERTFNLKFIRPFMQYNSTRAGG

Mouse                         RGMAFFGLTEFQRKTQYLFERTFNLKFIRPFMQYNSTRAGG

Chicken                       KDMAFFGLTEFQRKTQYLFERTFNLKFIRPFMQYNSTRAGG

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 411 Heparan-sulfate 6-O-sulfotransferase 1
Topological domain 38 – 411 Lumenal
Glycosylation 320 – 320 N-linked (GlcNAc...) asparagine



Literature citations
Heparan sulfate 6-O-sulfotransferase 1, a gene involved in extracellular sugar modifications, is mutated in patients with idiopathic hypogonadotrophic hypogonadism.
Tornberg J.; Sykiotis G.P.; Keefe K.; Plummer L.; Hoang X.; Hall J.E.; Quinton R.; Seminara S.B.; Hughes V.; Van Vliet G.; Van Uum S.; Crowley W.F.; Habuchi H.; Kimata K.; Pitteloud N.; Bulow H.E.;
Proc. Natl. Acad. Sci. U.S.A. 108:11524-11529(2011)
Cited for: FUNCTION; CATALYTIC ACTIVITY; VARIANTS HH15 TRP-306; GLN-306; GLN-323; TRP-382 AND VAL-404; CHARACTERIZATION OF VARIANTS HH15 TRP-306; GLN-306; GLN-323; TRP-382 AND VAL-404; The prevalence of CHD7 missense versus truncating mutations is higher in patients with Kallmann syndrome than in typical CHARGE patients.
Marcos S.; Sarfati J.; Leroy C.; Fouveaut C.; Parent P.; Metz C.; Wolczynski S.; Gerard M.; Bieth E.; Kurtz F.; Verier-Mine O.; Perrin L.; Archambeaud F.; Cabrol S.; Rodien P.; Hove H.; Prescott T.; Lacombe D.; Christin-Maitre S.; Touraine P.; Hieronimus S.; Dewailly D.; Young J.; Pugeat M.; Hardelin J.P.; Dode C.;
J. Clin. Endocrinol. Metab. 99:E2138-2143(2014)
Cited for: VARIANTS HH15 SER-218; GLN-306 AND TRP-306;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.